Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers

Author： Tarhini Ahmad A Kirkwood John M Krieg Arthur M

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.4, Iss.5, 2009-05, pp. : 587-603

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Toll-like receptor 9 agonists as cancer therapeutics

By Holtick Udo Scheulen Max E von Bergwelt-Baildon Michael S Weihrauch Martin R

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 361-372

Informa Healthcare

Access to resources Recommend Favorite

A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases

By Gupta Kaveri

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Modifying Toll-like Receptor 9 Signaling for Therapeutic Use

Mini Reviews in Medicinal Chemistry, Vol. 6, Iss. 3, 2006-03 ,pp. : 287-291

Bentham Science Publishers

Access to resources Recommend Favorite

Activation and Regulation of Toll-like Receptor 9: CpGs and Beyond

Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 6, 2008-06 ,pp. : 590-600

Bentham Science Publishers

Access to resources Recommend Favorite

Aminobisphosphonates and Toll-Like Receptor Ligands: Recruiting V&ggr;9Vδ2 T Cells for the Treatment of Hematologic Malignancy

Current Medicinal Chemistry, Vol. 18, Iss. 34, 2011-12 ,pp. : 5206-5216

Bentham Science Publishers

Access to resources Recommend Favorite